{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T22:09:25Z","timestamp":1761516565424,"version":"build-2065373602"},"reference-count":43,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["aacejournalendocrinepractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrine Practice"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.4158\/ep171910.or","type":"journal-article","created":{"date-parts":[[2018,2,21]],"date-time":"2018-02-21T12:38:50Z","timestamp":1519216730000},"page":"179-188","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Zoledronic Acid Versus Alendronate In The Treatment of Children With Osteogenesis Imperfecta: A 2-Year Clinical Study"],"prefix":"10.1016","volume":"24","author":[{"given":"Fang","family":"Lv","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaojie","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuwen","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lujiao","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan.","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ou.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weibo.","family":"Xia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoping.","family":"Xing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mei.","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.4158\/EP171910.OR_bb0010","first-page":"439","volume":"90","author":"Cundy","year":"2012","journal-title":"Recent advances in osteogenesis imperfecta"},{"key":"10.4158\/EP171910.OR_bb0015","first-page":"343","volume":"91","author":"Cho","year":"2012","journal-title":"A single recurrent mutation in the 5'-UTR of IFITM5 causes osteogenesis imperfecta type V"},{"key":"10.4158\/EP171910.OR_bb0020","first-page":"2798","volume":"26","author":"Homan","year":"2011","journal-title":"Mutations in SERPINF1 cause osteogenesis imperfecta type VI"},{"key":"10.4158\/EP171910.OR_bb0025","first-page":"2757","volume":"355","author":"Barnes","year":"2006","journal-title":"Deficiency of cartilage-associated protein in recessive lethal osteogenesis imperfecta"},{"key":"10.4158\/EP171910.OR_bb0030","first-page":"359","volume":"39","author":"Cabral","year":"2007","journal-title":"Prolyl 3-hydroxylase 1 deficiency causes a recessive metabolic bone disorder resembling lethal\/severe osteogenesis imperfecta"},{"key":"10.4158\/EP171910.OR_bb0035","first-page":"590","volume":"92","author":"Pyott","year":"2013","journal-title":"WNT1 mutations in families affected by moderately severe and progressive recessive osteogenesis imperfecta"},{"key":"10.4158\/EP171910.OR_bb0040","first-page":"1448","volume":"155A","author":"Shaheen","year":"2011","journal-title":"Mutations in FKBP10 cause both Bruck syndrome and isolated osteogenesis imperfecta in humans"},{"key":"10.4158\/EP171910.OR_bb0045","first-page":"1041","volume":"1","author":"Sillence","year":"1978","journal-title":"Classification of osteogenesis imperfect"},{"key":"10.4158\/EP171910.OR_bb0050","first-page":"2027","volume":"363","author":"Favus","year":"2010","journal-title":"Bisphosphonates for osteoporosis"},{"key":"10.4158\/EP171910.OR_bb0055","first-page":"346","volume":"75","author":"Vuorimies","year":"2011","journal-title":"Zoledronic acid treatment in children with osteogenesis imperfecta"},{"key":"10.4158\/EP171910.OR_bb0060","first-page":"132","volume":"21","author":"DiMeglio","year":"2006","journal-title":"Two-year clinical trial of oral alendronate versus intravenous pamidronate in children with osteogenesis imperfecta"},{"key":"10.4158\/EP171910.OR_bb0065","first-page":"300","volume":"21","author":"Chevrel","year":"2006","journal-title":"Effects of oral alendronate on BMD in adult patients with osteogenesis imperfecta: a 3-year randomized placebo-controlled trial"},{"key":"10.4158\/EP171910.OR_bb0070","first-page":"CD005088","volume":"10","author":"Dwan","year":"2016","journal-title":"Bisphosphonate therapy for osteogenesis imperfecta"},{"key":"10.4158\/EP171910.OR_bb0075","first-page":"485","volume":"25","author":"Barros","year":"2012","journal-title":"Safety and efficacy of a 1-year treatment with zoledronic acid compared with pamidronate in children with osteogenesis imperfecta"},{"key":"10.4158\/EP171910.OR_bb0080","first-page":"1424","volume":"382","author":"Bishop","year":"2013","journal-title":"Risedronate in children with osteogenesis imperfecta: a randomised, double-blind, placebo-controlled trial"},{"key":"10.4158\/EP171910.OR_bb0085","first-page":"e82098","volume":"8","author":"Xu","year":"2013","journal-title":"Bone mineral density of the spine in 11,898 Chinese infants and young children: a cross-sectional study"},{"key":"10.4158\/EP171910.OR_bb0090","first-page":"810","volume":"48","author":"Khadilkar","year":"2011","journal-title":"Normative data and percentile curves for dual energy X-ray absorptiometry in healthy Indian girls and boys aged 5\u201317 years"},{"key":"10.4158\/EP171910.OR_bb0095","first-page":"487","volume":"47","author":"Li","year":"2009","journal-title":"Height and weight standardized growth charts for Chinese children and adolescents aged 0 to 18 year"},{"key":"10.4158\/EP171910.OR_bb0100","first-page":"2239","volume":"25","author":"Orwoll","year":"2010","journal-title":"Efficacy and safety of a once-yearly i.v. Infusion of zoledronic acid 5 mg versus a once-weekly 70-mg oral alendronate in the treatment of male osteoporosis: a randomized, multicenter, double-blind, active-controlled study"},{"key":"10.4158\/EP171910.OR_bb0105","first-page":"355","volume":"96","author":"Ward","year":"2011","journal-title":"Alendronate for the treatment of pediatric osteogenesis imperfecta: a randomized placebo-controlled study"},{"key":"10.4158\/EP171910.OR_bb0110","first-page":"81","volume":"27","author":"Otaify","year":"2016","journal-title":"Zoledronic acid in children with osteogenesis imperfecta and Bruck syndrome: a 2-year prospective observational study"},{"key":"10.4158\/EP171910.OR_bb0115","first-page":"32","volume":"25","author":"Bishop","year":"2010","journal-title":"A randomized, controlled dose-ranging study of risedronate in children with moderate and severe osteogenesis imperfecta"},{"key":"10.4158\/EP171910.OR_bb0120","first-page":"1013","volume":"34","author":"Braga","year":"2004","journal-title":"Bone turnover markers in patients with osteogenesis imperfecta"},{"key":"10.4158\/EP171910.OR_bb0125","first-page":"461","volume":"44","author":"Garnero","year":"2009","journal-title":"Bone turnover and type I collagen C-telopeptide isomerization in adult osteogenesis imperfecta: associations with collagen gene mutations"},{"key":"10.4158\/EP171910.OR_bb0130","first-page":"1238","volume":"40","author":"Saag","year":"2007","journal-title":"A single zoledronic acid infusion reduces bone resorption markers more rapidly than weekly oral alendronate in postmenopausal women with low bone mineral density"},{"key":"10.4158\/EP171910.OR_bb0135","first-page":"617","volume":"38","author":"Nancollas","year":"2006","journal-title":"Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite"},{"key":"10.4158\/EP171910.OR_bb0140","first-page":"1427","volume":"363","author":"Sakkers","year":"2004","journal-title":"Skeletal effects and functional outcome with olpadronate in children with osteogenesis imperfecta: a 2-year randomised placebo-controlled study"},{"key":"10.4158\/EP171910.OR_bb0145","first-page":"126","volume":"18","author":"Adami","year":"2003","journal-title":"Intravenous neridronate in adults with osteogenesis imperfecta"},{"key":"10.4158\/EP171910.OR_bb0150","first-page":"55","volume":"22","author":"Brown","year":"2009","journal-title":"Safety and efficacy of intravenous zoledronic acid in paediatric osteoporosis"},{"key":"10.4158\/EP171910.OR_bb0155","first-page":"929","volume":"30","author":"Hald","year":"2015","journal-title":"Bisphosphonates for the prevention of fractures in osteogenesis imperfecta: meta-analysis of placebo-controlled trials"},{"key":"10.4158\/EP171910.OR_bb0160","first-page":"758","volume":"20","author":"Gatti","year":"2005","journal-title":"Intravenous neridronate in children with osteogenesis imperfecta: a randomized controlled study"},{"key":"10.4158\/EP171910.OR_bb0165","first-page":"977","volume":"20","author":"Letocha","year":"2005","journal-title":"Controlled trial of pamidronate in children with types III and IV osteogenesis imperfecta confirms vertebral gains but not short-term functional improvement"},{"key":"10.4158\/EP171910.OR_bb0170","first-page":"1449","volume":"31","author":"Vasanwala","year":"2016","journal-title":"Recurrent proximal femur fractures in a teenager with osteogenesis imperfecta on continuous bisphosphonate therapy: are we overtreating?"},{"key":"10.4158\/EP171910.OR_bb0175","first-page":"2150","volume":"30","author":"Palomo","year":"2015","journal-title":"Intravenous bisphosphonate therapy of young children with osteogenesis imperfecta: skeletal findings during follow up throughout the growing years"},{"key":"10.4158\/EP171910.OR_bb0180","first-page":"786","volume":"25","author":"Seikaly","year":"2005","journal-title":"Impact of alendronate on quality of life in children with osteogenesis imperfecta"},{"key":"10.4158\/EP171910.OR_bb0185","first-page":"43","volume":"18","author":"Dimeglio","year":"2005","journal-title":"A comparison of oral and intravenous bisphosphonate therapy for children with osteogenesis imperfecta"},{"key":"10.4158\/EP171910.OR_bb0190","first-page":"1282","volume":"24","author":"Rauch","year":"2009","journal-title":"Risedronate in the treatment of mild pediatric osteogenesis imperfecta: a randomized placebo-controlled study"},{"key":"10.4158\/EP171910.OR_bb0195","first-page":"566","volume":"98","author":"Ward","year":"2016","journal-title":"Osteogenesis imperfecta type VI in individuals from Northern Canada"},{"key":"10.4158\/EP171910.OR_bb0200","first-page":"4163","volume":"100","author":"George","year":"2015","journal-title":"Short-term safety of zoledronic acid in young patients with bone disorders: an extensive institutional experience"},{"key":"10.4158\/EP171910.OR_bb0205","first-page":"76","volume":"42","author":"Harcke","year":"2012","journal-title":"Fracture after bisphosphonate treatment in children with cerebral palsy: the role of stress risers"},{"key":"10.4158\/EP171910.OR_bb0210","first-page":"757","volume":"36","author":"Hegazy","year":"2016","journal-title":"Unusual femur stress fractures in children with osteogenesis imperfecta and intramedullary rods on long-term intravenous pamidronate therapy"},{"key":"10.4158\/EP171910.OR_bb0215","first-page":"457","volume":"349","author":"Whyte","year":"2003","journal-title":"Bisphosphonate-induced osteopetrosis"},{"key":"10.4158\/EP171910.OR_bb0220","first-page":"752","volume":"44","author":"Foley","year":"2009","journal-title":"Tracking of bone mass from childhood to adolescence and factors that predict deviation from tracking"}],"container-title":["Endocrine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X20354008?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X20354008?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T22:04:37Z","timestamp":1761516277000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1530891X20354008"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2]]},"references-count":43,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["S1530891X20354008"],"URL":"https:\/\/doi.org\/10.4158\/ep171910.or","relation":{},"ISSN":["1530-891X"],"issn-type":[{"type":"print","value":"1530-891X"}],"subject":[],"published":{"date-parts":[[2018,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Zoledronic Acid Versus Alendronate In The Treatment of Children With Osteogenesis Imperfecta: A 2-Year Clinical Study","name":"articletitle","label":"Article Title"},{"value":"Endocrine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.4158\/EP171910.OR","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}